# AURELIA

Source: https://onco.cc/trials/aurelia/  
OnCo record `aurelia` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AURELIA showed that adding bevacizumab to single-drug chemotherapy for ovarian cancer that has stopped responding to platinum doubled the time before the cancer grew again, from 3.4 to 6.7 months, and more than doubled the response rate, though it did not clearly lengthen life.

## Summary

AURELIA was an open-label phase 3 trial in 361 women with platinum-resistant ovarian cancer randomised to the investigator's choice of weekly paclitaxel, pegylated liposomal doxorubicin or topotecan, alone or with bevacizumab. The primary endpoint was progression-free survival.

Median progression-free survival was 6.7 months with bevacizumab against 3.4 months with chemotherapy alone (hazard ratio 0.48), the response rate 27.3 against 11.8 percent and median overall survival 16.6 against 13.3 months (hazard ratio 0.85, not significant). Hypertension and proteinuria were more common with bevacizumab and gastrointestinal perforation occurred in 2.2 percent. The trial led to approval of bevacizumab with chemotherapy for platinum-resistant disease in the United States in November 2014, which is how the corpus's platinum-resistant ovarian cancer page cites it.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-22
- Also known as: MO22224
- Tags: soc-trials
- Registry id: NCT00976911
- Phase: 3
- Setting: Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer after no more than two prior regimens: the investigator's single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin or topotecan) with or without bevacizumab, with progression-free survival as the primary endpoint
- Sponsor: Hoffmann-La Roche
- Enrolled: 361
- Result: Median progression-free survival 6.7 months with bevacizumab plus chemotherapy against 3.4 months with chemotherapy alone (hazard ratio 0.48, p < 0.001); response rate 27.3 against 11.8 percent; overall survival not significantly different (16.6 against 13.3 months).
- Outcomes: Progression-free survival: Bevacizumab + single-agent chemotherapy 6.7 months vs Single-agent chemotherapy 3.4 months, HR 0.48; Progression-free survival (registry results, November 2011 cut-off): Bevacizumab + single-agent chemotherapy 6.8 months vs Single-agent chemotherapy 3.4 months, HR 0.46; Objective response rate (RECIST): Bevacizumab + single-agent chemotherapy 27.3% vs Single-agent chemotherapy 11.8%; Overall survival: Bevacizumab + single-agent chemotherapy 16.6 months vs Single-agent chemotherapy 13.3 months, HR 0.85; Gastrointestinal perforation: Bevacizumab + single-agent chemotherapy 2.2%

## Sources

- ClinicalTrials.gov NCT00976911: https://clinicaltrials.gov/study/NCT00976911

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- key papers: [AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer](https://onco.cc/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/)

---
JSON: https://onco.cc/api/v1/entities/aurelia.json